ASX Announcements Archive 2009
22 Dec 2009
Commencement of Circadian non-executive director share plan
07 Dec 2009
Circadian and CSIRO enter strategic research alliance
19 Nov 2009
Results of Annual General Meeting
19 Nov 2009
2009 AGM Managing Director's Presentation
10 Nov 2009
CIR to present at Merriman Curhan Ford's US Investor Summit
29 Oct 2009
Circadian subsidiary terminates licence to Ark Therapeutics
16 Oct 2009
Open Briefing - CEO on Manufacturing Milestone and Update
14 Oct 2009
2009 Annual Report
14 Oct 2009
Notice of Annual General Meeting
13 Oct 2009
Manuafacturing milestone achieved for cancer drug candidate VGX-300
14 Sep 2009
Change of date for Circadian's 2009 AGM
09 Sep 2009
Change of Director's Interest Notice - Robert Klupacs
08 Sep 2009
Change in substantial holder
07 Sep 2009
Circadian provides PerkinElmer with worldwide rights to market research products
03 Sep 2009
Circadian Newsletter - September 2009
25 Aug 2009
Circadian granted key VEGF-C patent in Japan
25 Aug 2009
Initial Director's Interest Notice - Dr Errol Malta
20 Aug 2009
Dr Errol Malta appointed non-executive director
20 Aug 2009
Preliminary final report
30 Jul 2009
Shares to be released from escrow
09 Jul 2009
Corporate Presentation
30 Jun 2009
Appendix 3B - Employee incentive
18 Jun 2009
Circadian granted key strategic VEGF-D patent in Europe for angiogenic applications
03 Jun 2009
Circadian sponsors international conference on angiogenesis research
22 May 2009
Circadian licensee Ark Therapeutics announces Trinam phase III study enrols first patient
19 May 2009
Open Briefing - CEO on Recent Achievements
13 May 2009
FINSIA presentation - "The Survivors: strong business and balance sheet"
06 May 2009
Circadian Scientific Advisory Board Chairman, Prof. Kari Alitalo, wins prestigious award for...
24 Apr 2009
Change of Director's Interest Notice - Dominique Fisher
24 Apr 2009
BioMelbourne Network presentation - Transformation of Circadian
22 Apr 2009
Circadian partner ImClone Systems demonstrates VEGFR-3 antibody improves anti-tumour effects of...
02 Apr 2009
Circadian Newsletter - April 2009
26 Mar 2009
Corporate Presentation
02 Mar 2009
Open Briefing on Cancer Diagnostic Commercialisation
25 Feb 2009
Circadian and Healthscope to commercialise Peter Mac Cancer Diagnostic
09 Feb 2009
Half-Year Results & Operational Achievements
22 Jan 2009
Open Briefing - CEO on Trinam Phase III Trial
09 Jan 2009
Ark Therapeutics receives clearance to commence Phase 3 trial of Trinam